Supernus Pharmaceuticals annual diluted eps
Diluted EPSBasic EPS
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals EPS History: Annual & Quarterly (SUPN)
Supernus Pharmaceuticals's diluted EPS was -$0.68 for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | -$0.68 | -$0.68 | -$2.00 | — |
| 2024 | 2024-12-31 | $1.32 | $1.34 | $1.30 | +6500.00% |
| 2023 | 2023-12-31 | $0.02 | $0.02 | -$1.02 | −98.08% |
| 2022 | 2022-12-31 | $1.04 | $1.13 | $0.06 | +6.12% |
| 2021 | 2021-12-31 | $0.98 | $1.01 | -$1.38 | −58.47% |
| 2020 | 2020-12-31 | $2.36 | $2.41 | $0.26 | +12.38% |
| 2019 | 2019-12-31 | $2.10 | $2.16 | $0.05 | +2.44% |
| 2018 | 2018-12-31 | $2.05 | $2.13 | $0.97 | +89.81% |
| 2017 | 2017-12-31 | $1.08 | $1.13 | -$0.68 | −38.64% |
| 2016 | 2016-12-31 | $1.76 | $1.84 | $1.48 | +528.57% |
| 2015 | 2015-12-31 | $0.28 | $0.29 | $0.54 | — |
| 2014 | 2014-12-31 | -$0.26 | -$0.26 | $2.64 | — |
| 2013 | 2013-12-31 | -$2.90 | -$2.90 | -$0.18 | — |
| 2012 | 2012-12-31 | -$2.72 | -$2.72 | -$34.11 | — |
| 2011 | 2011-12-31 | $31.39 | $31.39 | $57.77 | — |
| 2010 | 2010-12-31 | -$26.38 | -$26.38 | — | — |
Supernus Pharmaceuticals quarterly diluted eps
Diluted EPSBasic EPS
Q1.11
Q2.11
Q3.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$1.01 | -$1.01 | -$1.41 | — |
| Q1 2026 | 2026-03-31 | -$0.04 | -$0.04 | $0.17 | — |
| Q4 2025 | 2025-12-31 | -$0.07 | -$0.07 | — | — |
| Q3 2025 | 2025-09-30 | -$0.80 | -$0.80 | -$1.49 | — |
| Q2 2025 | 2025-06-30 | $0.40 | $0.40 | $0.04 | +11.11% |
| Q1 2025 | 2025-03-31 | -$0.21 | -$0.21 | -$0.21 | — |
| Q3 2024 | 2024-09-30 | $0.69 | $0.70 | $0.98 | — |
| Q2 2024 | 2024-06-30 | $0.36 | $0.36 | $0.38 | — |
| Q1 2024 | 2024-03-31 | $0.00 | $0.00 | -$0.29 | — |
| Q3 2023 | 2023-09-30 | -$0.29 | -$0.29 | -$0.32 | — |
| Q2 2023 | 2023-06-30 | -$0.02 | -$0.02 | -$0.16 | — |
| Q1 2023 | 2023-03-31 | $0.29 | $0.31 | -$0.14 | −32.56% |
| Q3 2022 | 2022-09-30 | $0.03 | $0.03 | -$0.37 | −92.50% |
| Q2 2022 | 2022-06-30 | $0.14 | $0.15 | -$0.29 | −67.44% |
| Q1 2022 | 2022-03-31 | $0.43 | $0.48 | $0.32 | +290.91% |
| Q3 2021 | 2021-09-30 | $0.40 | $0.41 | -$0.34 | −45.95% |
| Q2 2021 | 2021-06-30 | $0.43 | $0.45 | -$0.22 | −33.85% |
| Q1 2021 | 2021-03-31 | $0.11 | $0.11 | -$0.29 | −72.50% |
| Q3 2020 | 2020-09-30 | $0.74 | $0.76 | $0.20 | +37.04% |
| Q2 2020 | 2020-06-30 | $0.65 | $0.66 | $0.04 | +6.56% |
| Q1 2020 | 2020-03-31 | $0.40 | $0.41 | $0.06 | +17.65% |
| Q4 2019 | 2019-12-31 | $0.62 | $0.63 | $0.14 | +29.17% |
| Q3 2019 | 2019-09-30 | $0.54 | $0.55 | $0.02 | +3.85% |
| Q2 2019 | 2019-06-30 | $0.61 | $0.62 | $0.04 | +7.02% |
| Q1 2019 | 2019-03-31 | $0.34 | $0.35 | -$0.15 | −30.61% |
| Q4 2018 | 2018-12-31 | $0.48 | $0.50 | $0.22 | +84.62% |
| Q3 2018 | 2018-09-30 | $0.52 | $0.54 | $0.23 | +79.31% |
| Q2 2018 | 2018-06-30 | $0.57 | $0.59 | $0.25 | +78.12% |
| Q1 2018 | 2018-03-31 | $0.49 | $0.51 | $0.30 | +157.89% |
| Q4 2017 | 2017-12-31 | $0.26 | $0.27 | $0.00 | 0.00% |
| Q3 2017 | 2017-09-30 | $0.29 | $0.31 | -$0.89 | −75.42% |
| Q2 2017 | 2017-06-30 | $0.32 | $0.34 | $0.14 | +77.78% |
| Q1 2017 | 2017-03-31 | $0.19 | $0.21 | $0.11 | +137.50% |
| Q4 2016 | 2016-12-31 | $0.26 | $0.29 | $0.12 | +85.71% |
| Q3 2016 | 2016-09-30 | $1.18 | $1.25 | $1.10 | +1375.00% |
| Q2 2016 | 2016-06-30 | $0.18 | $0.21 | $0.14 | +350.00% |
| Q1 2016 | 2016-03-31 | $0.08 | $0.10 | $0.06 | +300.00% |
| Q4 2015 | 2015-12-31 | $0.14 | $0.14 | $0.05 | +55.56% |
| Q3 2015 | 2015-09-30 | $0.08 | $0.08 | $0.14 | — |
| Q2 2015 | 2015-06-30 | $0.04 | $0.05 | -$0.04 | −50.00% |
| Q1 2015 | 2015-03-31 | $0.02 | $0.02 | $0.40 | — |
| Q4 2014 | 2014-12-31 | $0.09 | $0.09 | $0.74 | — |
| Q3 2014 | 2014-09-30 | -$0.06 | -$0.06 | $0.72 | — |
| Q2 2014 | 2014-06-30 | $0.08 | $0.08 | $0.97 | — |
| Q1 2014 | 2014-03-31 | -$0.38 | -$0.38 | $0.22 | — |
| Q4 2013 | 2013-12-31 | -$0.65 | -$0.65 | -$0.14 | — |
| Q3 2013 | 2013-09-30 | -$0.78 | -$0.78 | -$0.23 | — |
| Q2 2013 | 2013-06-30 | -$0.89 | -$0.89 | -$0.28 | — |
| Q1 2013 | 2013-03-31 | -$0.60 | -$0.60 | $5.45 | — |
| Q4 2012 | 2012-12-31 | -$0.51 | -$0.51 | — | — |
| Q3 2012 | 2012-09-30 | -$0.55 | -$0.55 | $6.09 | — |
| Q2 2012 | 2012-06-30 | -$0.61 | -$0.61 | $4.56 | — |
| Q1 2012 | 2012-03-31 | -$6.05 | -$6.05 | $1.43 | — |
| Q3 2011 | 2011-09-30 | -$6.64 | -$6.64 | — | — |
| Q2 2011 | 2011-06-30 | -$5.17 | -$5.17 | — | — |
| Q1 2011 | 2011-03-31 | -$7.48 | -$7.48 | — | — |
Supernus Pharmaceuticals diluted eps trends
Over the last five fiscal years, Supernus Pharmaceuticals's diluted eps decreased from $2.36 to -$0.68, a change of -$3.04. The latest reported quarter, Q2 2026, shows -$1.01.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
